AUS
NZ
UK
CA
USA
IND
Eli Lilly is gaining significant attention as its market capitalization approaches $1 trillion, driven largely by optimism surrounding its anti-obesity drugs. This surge in interest may overshadow other pharmaceutical companies creating opportunities for those looking to explore less heralded stocks in the sector.
One such company that might eventually join the trillion-dollar ranks is Johnson & Johnson (NASDAQ:JNJ). Historically, the list of companies with valuations over $1 trillion has been dominated by technology firms. However, pharmaceutical companies are not far behind, and Johnson & Johnson could be a future member of this exclusive group.
Johnson & Johnson is a leading player in the pharmaceutical industry, having reported substantial revenue and dominating global pharmaceutical sales. For the most recent fiscal year, its revenue significantly surpassed that of other major pharmaceutical competitors.
Johnson & Johnson offers a compelling option. Its current market value is under $400 billion, indicating significant growth over the coming years. While reaching a $1 trillion valuation will likely take time, Johnson & Johnson remains a strong candidate for sustained, stable growth in the NASDAQ Healthcare Stock.
In terms of valuation, Johnson & Johnson is not cheap, but it trades at a discount compared to some peers and its own historical levels. The company's enterprise-value-to-EBITDA (EV/EBITDA) ratio is in line with industry norms, making its valuation seem reasonable when compared to its competitors. Moreover, the stock is relatively inexpensive based on historical metrics, including forward P/E ratios and price-to-free cash flow, suggesting it might be a good value.
Interest rates, currently at high levels, have exerted downward pressure on stock prices, affecting various sectors differently. While tech stocks have seen high valuations due to AI trends, the pharmaceutical sector, including Johnson & Johnson, appears to be benefiting from lower relative valuations.
Despite for a decline in sales from patent expirations, Johnson & Johnson's diverse product portfolio and robust pipeline of future treatments help mitigate these risks. The company maintains a strong dividend yield, reflecting its financial stability and commitment to returning value to shareholders.
